MREO (Mereo BioPharma Group) Volatility: 94.83% (As of Jul. 04, 2026)


MREO Mereo BioPharma Group PLC MREO
19 GF Score
Price $0.33
! 1 Warning Sign
View Full Analysis

What is Mereo BioPharma Group Volatility?

Mereo BioPharma Group MREO +3.62% 19 Volatility is 94.83% as of Jul. 04, 2026. GuruFocus rates MREO with a GF Score™ of 19/100. The stock has 1 warning sign investors should review.

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2026-07-04), Mereo BioPharma Group's Volatility is 94.83%.


Mereo BioPharma Group  (NAS:MREO) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.


Mereo BioPharma Group Volatility Related Terms


MREO vs VRTX, REGN, ALNY: Volatility Comparison

For the Biotechnology subindustry, Mereo BioPharma Group's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mereo BioPharma Group Volatility vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mereo BioPharma Group's Volatility distribution charts can be found below:

* The bar in red indicates where Mereo BioPharma Group's Volatility falls into.


MREO
19GF Score
Mereo BioPharma Group PLC MREO
Volatility is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mereo BioPharma Group  (NAS:MREO) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * 12
= 1/(n-1) ∑(Ri - R')^2 * 12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Volatility →
What does a Volatility of 94.83% mean?
Mereo BioPharma Group (MREO) has a Volatility of 94.83% as of Jul. 04, 2026. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Mereo BioPharma Group and its competitors.
Is Mereo BioPharma Group's Volatility too high?
Mereo BioPharma Group's current Volatility is 94.83%. Overall, Mereo BioPharma Group has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Mereo BioPharma Group's Volatility compare to VRTX and REGN?
Mereo BioPharma Group's Volatility of 94.83% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Volatility for a Biotechnology company?
A good Volatility depends on the Biotechnology industry context. However, Volatility should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Volatility mean?
A high Volatility can signal that a stock is expensive relative to its fundamentals. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Mereo BioPharma Group and its competitors. Mereo BioPharma Group's current Volatility is 94.83%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mereo BioPharma Group stock overvalued right now?
Mereo BioPharma Group (MREO) has a current Volatility of 94.83%. The current Volatility is 94.83%. Mereo BioPharma Group's overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Volatility calculated?
Volatility is calculated from a company's financial statements. For Mereo BioPharma Group (MREO), the current Volatility is 94.83% as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mereo BioPharma Group Business Description

Other Exchanges 0A9G:UKMAH0:Germany
Address One Cavendish Place, 4th Floor, London, GBR, W1G 0QF
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
19GF Score

Get the complete analysis for MREO

Volatility is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.33
Price